(Reuters) - Onyx Pharmaceuticals Inc (ONXX.O) said on Sunday it sued Bayer AG (BAYG.DE) over its rights to an anti-cancer compound that it says it discovered during joint research with the German drugmaker.
Onyx's lawsuit, filed in the U.S. District Court for the Northern District of California, seeks a declaration that fluoro-sorafenib is a jointly owned collaboration compound under an agreement between the two companies.
Onyx said it learned that the compound is a variant of Nexavar tablets, which Onyx and Bayer co-develop and market.
The company said fluoro-sorafenib has the same chemical structure as Nexavar except that fluoro-sorafenib contains a fluorine atom instead of a hydrogen atom.
"The new molecule had been identified in 1998 during the research collaboration period by the companies' joint research teams," Onyx said in a statement. "Discussions with Bayer regarding Onyx's rights to fluoro-sorafenib under the companies' 1994 collaboration agreement were not productive."
Doctors use Nexavar to treat liver cancer and advanced kidney cancer. Onyx and Bayer co-developed Nexavar and have marketed the drug in the United States and other countries.
Bayer said it disagrees with Onyx.
"We plan to defend ourselves against the complaint as we believe that Onyx has no rights to the substance," Bayer said in an e-mailed statement.
A hearing has not been scheduled yet, an Onyx spokeswoman said.
Onyx's revenue from its agreement rose 10 percent to $53.7 million in the first quarter of this year, it said on May 6.
Read more here
Sunday, May 17, 2009
Biotech Jobs Germinate as San Francisco Diversifies Economy
(Bloomberg) -- A once-vacant rail yard 2 miles from downtown San Francisco is coming to life as a center of biotechnology and transforming San Francisco’s economy beyond tourism and financial services.
San Francisco is too dependent on those industries, says Mayor Gavin Newsom, who’s using a tax cut and other incentives to woo businesses with growth potential. He’s especially targeting biotechnology, which has a foothold in the city’s emerging biomedical district known as Mission Bay.
Pfizer Inc., the world’s largest drugmaker, will open a five-story biotechnology headquarters in Mission Bay next year. At a so-called biotech hotel, where start-ups rent space, a scientist studies tissue samples for Groningen, Netherlands- based Brains On-Line BV. Partners at Versant Ventures and other venture capital firms on the hotel’s top floor can look out at the industry they’re funding.
“This area is going to pop,” said Gail Maderis, chief executive officer of FivePrime Therapeutics, the first biotechnology company to move to Mission Bay. “We have pharma and biotech companies coming through all the time and they look and see Mission Bay growing. This will be the largest life sciences hub west of the Rockies.”
Newsom, 41, sweetened the appeal to biotech companies by waiving the 1.25 percent payroll tax through 2015, allowing extra parking spaces and expediting building permits.
“Five years ago, there were three biotech companies in the city; now there’s 47,” Newsom, a Democrat running for California governor, said in an interview. “I have great confidence that things will continue to advance.”
Growth by Diversifying
Biotech companies added 300 jobs in the city last year as it lost a total of 20,000. About one of every seven jobs in San Francisco is tied to tourism, out of a daily workforce of about 550,000, according to the state Employment Development Department.
“Diversifying the economy is absolutely a good thing to do,” said George Jouganatos, an economic consultant in Sacramento who teaches at California State University. “San Francisco has a large financial sector, which is in decline, and the tourism business is in somewhat of a decline.”
The city’s budget this fiscal year is $6.5 billion, said Ted Egan, chief economist. Hotel tax revenues fell 30 percent in February and 20 percent in March from a year earlier, he said. Hotel occupancy fell to 60 percent in February from 74 percent a year earlier.
The biotechnology cluster is growing on a former rail yard south of downtown. The site once crisscrossed with sidings and spurs was deserted in the 1960s when shipping shifted across the bay to Oakland.
University Leads Way
After a redevelopment plan was approved in 1998, the University of California at San Francisco built three biomedical research facilities, a community center and four apartment buildings for students and staff. The biotech industry eventually followed.
FivePrime, a closely held company that’s identifying protein-based therapies, moved in 2005 from South San Francisco, home of Roche’s Genentech Inc. Savings from the tax waiver are enough to pay one scientist, said Maderis, 51. That’s a big boost for a 100-employee startup that’s 10 years from being profitable, she said.
Having a Mission Bay address helps recruit employees, said Alan Sachs, vice president of Merck & Co.’s research division. Whitehouse Station, New Jersey-based Merck’s Sirna Therapeutics unit will fully occupy its quarters next year, he said.
New York-based Pfizer will bring 120 workers when its building is completed, said Elizabeth Power, a spokeswoman.
Read more here
San Francisco is too dependent on those industries, says Mayor Gavin Newsom, who’s using a tax cut and other incentives to woo businesses with growth potential. He’s especially targeting biotechnology, which has a foothold in the city’s emerging biomedical district known as Mission Bay.
Pfizer Inc., the world’s largest drugmaker, will open a five-story biotechnology headquarters in Mission Bay next year. At a so-called biotech hotel, where start-ups rent space, a scientist studies tissue samples for Groningen, Netherlands- based Brains On-Line BV. Partners at Versant Ventures and other venture capital firms on the hotel’s top floor can look out at the industry they’re funding.
“This area is going to pop,” said Gail Maderis, chief executive officer of FivePrime Therapeutics, the first biotechnology company to move to Mission Bay. “We have pharma and biotech companies coming through all the time and they look and see Mission Bay growing. This will be the largest life sciences hub west of the Rockies.”
Newsom, 41, sweetened the appeal to biotech companies by waiving the 1.25 percent payroll tax through 2015, allowing extra parking spaces and expediting building permits.
“Five years ago, there were three biotech companies in the city; now there’s 47,” Newsom, a Democrat running for California governor, said in an interview. “I have great confidence that things will continue to advance.”
Growth by Diversifying
Biotech companies added 300 jobs in the city last year as it lost a total of 20,000. About one of every seven jobs in San Francisco is tied to tourism, out of a daily workforce of about 550,000, according to the state Employment Development Department.
“Diversifying the economy is absolutely a good thing to do,” said George Jouganatos, an economic consultant in Sacramento who teaches at California State University. “San Francisco has a large financial sector, which is in decline, and the tourism business is in somewhat of a decline.”
The city’s budget this fiscal year is $6.5 billion, said Ted Egan, chief economist. Hotel tax revenues fell 30 percent in February and 20 percent in March from a year earlier, he said. Hotel occupancy fell to 60 percent in February from 74 percent a year earlier.
The biotechnology cluster is growing on a former rail yard south of downtown. The site once crisscrossed with sidings and spurs was deserted in the 1960s when shipping shifted across the bay to Oakland.
University Leads Way
After a redevelopment plan was approved in 1998, the University of California at San Francisco built three biomedical research facilities, a community center and four apartment buildings for students and staff. The biotech industry eventually followed.
FivePrime, a closely held company that’s identifying protein-based therapies, moved in 2005 from South San Francisco, home of Roche’s Genentech Inc. Savings from the tax waiver are enough to pay one scientist, said Maderis, 51. That’s a big boost for a 100-employee startup that’s 10 years from being profitable, she said.
Having a Mission Bay address helps recruit employees, said Alan Sachs, vice president of Merck & Co.’s research division. Whitehouse Station, New Jersey-based Merck’s Sirna Therapeutics unit will fully occupy its quarters next year, he said.
New York-based Pfizer will bring 120 workers when its building is completed, said Elizabeth Power, a spokeswoman.
Read more here
Subscribe to:
Posts (Atom)
